Hepatocyte growth factor--a new marker for prognosis in acute coronary syndrome.
This study was designed to check the properties of hepatocyte growth factor (HGF) as a new marker of myocardial necrosis.


METHODS
In one hundred and four patients with acute coronary syndrome (ACS), plasma human HGF (hHGF) concentrations were assessed twice, i.e. just after admission to hospital and 24 h afterwards. The primary composite endpoint was assessed at three-month follow-up.


RESULTS
The maximal concentration of hHGF (1902 pg/ml) was reached at the time of admission to hospital due to ACS with significant decrease 24 h after the first measurement (705 pg/ml p < 0.0001). hHGF levels in ST segment elevation myocardial infarction (STEMI) were higher than in non-ST segment elevation myocardial infarction (NSTEMI) and in patients who reached composite primary endpoint (33 patients-4211 pg/ml) vs. event-free 71 patients (1013 pg/ml p < 0.01). The correlation between values of hHGF and N-terminal prohormone B-type natriuretic peptide and cardiac troponin I was revealed.


CONCLUSIONS
HGF is a very early, good marker of myocardial necrosis and a sensitive short- and long-term prognostic factor in ACS.
Konopka
Anna
A
Institute of Cardiology CCU, ul. Alpejska 42, Warsaw, Poland. akonopka@ptkardio.pl
Janas
Jadwiga
J
Piotrowski
Walerian
W
Stepińska
Janina
J
D054058:Acute Coronary Syndrome / Q000097:blood* / Q000401:mortality* / Q000503:physiopathology; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D017023:Coronary Angiography; D005260:Female; D017228:Hepatocyte Growth Factor / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D011379:Prognosis; D018570:Risk Assessment
D015415:Biomarkers; C066855:HGF protein, human; D017228:Hepatocyte Growth Factor